Aquestive Therapeutics Inc Quick Ratio (AQST) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aquestive Therapeutics Inc   (NASDAQ: AQST)

Aquestive Therapeutics Inc 's Quick Ratio

AQST's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Aquestive Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Aquestive Therapeutics Inc 's Quick Ratio to 5.98, above Aquestive Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 167 other companies have achieved higher Quick Ratio than Aquestive Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 632, from total ranking in the first quarter 2026 at 761.

Explain Quick Ratio?
How much Cash & cash equivalents AQST´s has?
What are AQST´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AQST Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -28.84 % 73.53 % 152.36 % 136.97 % 66.64 %
Y / Y Cash & cash equivalent Change 62.7 % 61.29 % - 65.69 % -32.64 %
Quick Ratio MRQ 5.98 3.49 - 5.05 2.61
AQST's Total Ranking # 632 # 761 # 0 # 556 # 574
Seq. Current Liabilities Change -48.11 % -33.3 % 86.16 % 10.45 % 26.54 %
Seq. Cash & cash equivalent Change -11.06 % - - 113.2 % -11.83 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 168
Healthcare Sector # 266
Overall Market # 632


Quick Ratio Statistics
High Average Low
6.47 2.17 0.41
(Jun 30 2024)   (Jun 30 2018)




Financial Statements
Aquestive Therapeutics Inc 's Current Liabilities $ 16 Millions Visit AQST's Balance sheet
Aquestive Therapeutics Inc 's Cash & cash equivalent $ 98 Millions Visit AQST's Balance sheet
Source of AQST's Sales Visit AQST's Sales by Geography


Cumulative Aquestive Therapeutics Inc 's Quick Ratio

AQST's Quick Ratio for the trailling 12 Months

AQST Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 70.74 % 107.1 % 86.07 % 40.68 % -4.32 %
Y / Y Cash & cash equivalent TTM Growth 63.36 % 27.03 % -1.79 % -1.79 % -1.38 %
Quick Ratio TTM 2.79 2.34 2.25 3.01 2.91
Total Ranking TTM # 3829 # 3829 # 2070 # 3070 # 2622
Seq. Current Liabilities TTM Growth -5.21 % 11.74 % 33.46 % 20.79 % 14.97 %
Seq. Cash & cash equivalent TTM Growth 12.64 % 16.29 % 0 % 24.71 % -12.41 %

Quick ratio ranking by company, industry and sector >> Back to AQST Financial Strength Comparisons >> Go to Compare AQST Quick Ratio to its Competitors

On the trailing twelve months basis AQST Cash & cash equivalent soared by 62.7 % in Q2 2026 year on year, while Current Liabilities dropped to $16 millions, this led to increase in in Aquestive Therapeutics Inc 's Quick Ratio to 2.79, above AQST average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Aquestive Therapeutics Inc . While overall ranking is unchanged compared to the previous 12 months at no. 3829.

Explain Quick Ratio?
How much Cash & cash equivalents AQST´s has?
What are AQST´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 431
Healthcare Sector # 880
Within the Market # 3829


trailing twelve months Quick Ratio Statistics
High Average Low
4.02 1.72 0.39
(Sep 30 2024)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Erasca Inc   16.41 $ 610.496  Millions$ 37.200  Millions
Janux Therapeutics Inc   16.14 $ 970.913  Millions$ 60.152  Millions
Edgewise Therapeutics inc   15.86 $ 460.709  Millions$ 29.042  Millions
Corvus Pharmaceuticals Inc   15.74 $ 215.200  Millions$ 13.672  Millions
Telomir Pharmaceuticals Inc   15.55 $ 5.170  Millions$ 0.332  Millions
Rapport Therapeutics Inc   15.34 $ 436.077  Millions$ 28.424  Millions
Lb Pharmaceuticals Inc  15.32 $ 369.576  Millions$ 24.128  Millions
Anixa Biosciences Inc   15.09 $ 26.330  Millions$ 1.745  Millions
Siga Technologies Inc  14.99 $ 117.584  Millions$ 7.845  Millions
Vyne Therapeutics Inc   14.87 $ 22.925  Millions$ 1.542  Millions
Alto Neuroscience Inc   14.64 $ 243.733  Millions$ 16.652  Millions
Tenax Therapeutics Inc   14.62 $ 118.000  Millions$ 8.073  Millions
Jade Biosciences Inc   14.61 $ 461.205  Millions$ 31.570  Millions
Immunome Inc   14.56 $ 519.996  Millions$ 35.713  Millions
Sensei Biotherapeutics Inc   14.54 $ 186.441  Millions$ 12.824  Millions
Cytokinetics Incorporated  14.39 $ 2,610.415  Millions$ 181.429  Millions
Canton Strategic Holdings Inc   14.18 $ 37.242  Millions$ 2.626  Millions
An2 Therapeutics Inc   14.04 $ 78.387  Millions$ 5.585  Millions
Aclaris Therapeutics Inc   13.97 $ 394.443  Millions$ 28.241  Millions
Pmv Pharmaceuticals Inc   13.85 $ 146.393  Millions$ 10.568  Millions
Generate Biomedicines Inc   13.76 $ 779.456  Millions$ 56.636  Millions
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions
Aprea Therapeutics Inc   13.33 $ 41.233  Millions$ 3.092  Millions
Polaryx Therapeutics Inc   13.22 $ 11.542  Millions$ 0.873  Millions
Monopar Therapeutics Inc   13.14 $ 52.758  Millions$ 4.016  Millions
Lexicon Pharmaceuticals Inc   12.96 $ 190.610  Millions$ 14.706  Millions
Korro Bio Inc   12.89 $ 162.805  Millions$ 12.628  Millions
Atea Pharmaceuticals Inc   12.89 $ 362.382  Millions$ 28.124  Millions

Date modified: 2026-09-26T07:39:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.